Novo Nordisk公司宣布美国食品与药物管理局批准了它们生产的Levemir?用于儿童糖尿病治疗。Levemir是一种新颖的长时效胰岛素注射剂, 它可提供24小时作用。用于成人的研究表明它几乎不改变体重。Novo Nordisk将在未来八个月内发行用于成人和儿童的Levemir。

About Levemir

Levemir is a soluble, long-acting basal insulin analogue. Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long acting) insulin for the control of hyperglycemia. Levemir has already been approved for use in 53 countries worldwide, including countries throughout Europe. Levemir was cleared for marketing in adults by the U.S. Food and Drug Administration in June 2005.